S.	Reviewer suggestion/	Changes made/ Reply	Manuscript		
No.	comment		page/ line number		
Revi	Reviewer 1				
1	The structure of this mini- review was confused to follow. In my opinion, the benefit and harm of incretin- based therapy and pancreatic cancer should be clearly clarified.	We sincerely thank the reviewers for their useful comments on our manuscript. The structure has been modified for better clarity. The benefits and the harms are explained clearly. However, drawing a definitive conclusion is difficult based upon current evidence and caution is still needed.	Page 3-11 Line 55-305		
2	A graphic explanation should be recommended	A flow chart depicting the pathogenesis is added.	Figure 1 Page-19 Line- 534-536		
3	The author concluded that "It seems that incretin-based therapies do not increase the risk for PC. Rather, new experimental data have shown some beneficial effects on cancer cells needing further evaluation.". Please discussed is there exist potential elements (For example History of pancreatitis or gastrointestinal tumors) that influence the effect of incretin.	We could not find any human studies evaluating the effect of incretin-based therapy in pancreatitis/ past history of GINET or pancreatic carcinoma. Evidence is limited to preclinical data. The word preclinical was added in the conclusion.	Page- 11 Line- 301-302		
4	Some format errors should be corrected	Conjugation and format errors have been rectified.	Page 3-11 Line 55-305		
5	Added full name in the manuscript when abbreviation used first time.		Page 3-11 Line 55-305		
Reviewer 2					
1	Some words are wrong, please read the full text and revise it carefully.	Conjugation and format errors have been rectified.	Page 3-11 Line 55-305		

Revi	ewer 3		
1	There are a few small conjugation problems here and there, therefore, a thorough reading is suggested	Conjugation and format errors have been rectified.	Page 3-11 Line 55-305
2		A table enlisting various incretin-based medications was added.	Table 1 Page- 19 Line- 530-533